Next quarter’s earnings estimate for ONCO is -kr0.19 with a range of -kr0.19 to -kr0.19. The previous quarter’s EPS was -kr0.27. ONCO beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year ONCO has Performed in-line its overall industry.
Next quarter’s earnings estimate for ONCO is -kr0.19 with a range of -kr0.19 to -kr0.19. The previous quarter’s EPS was -kr0.27. ONCO beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year ONCO has Performed in-line its overall industry.
ONCO Sales Forecast
Next quarter’s sales forecast for ONCO is kr33.00M with a range of kr33.00M to kr33.00M. The previous quarter’s sales results were kr20.21M. ONCO beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year ONCO has Performed in-line its overall industry.
Next quarter’s sales forecast for ONCO is kr33.00M with a range of kr33.00M to kr33.00M. The previous quarter’s sales results were kr20.21M. ONCO beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year ONCO has Performed in-line its overall industry.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
No data currently available
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
No data currently available
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Copying Dex Genotek 's trades and holding each position for 1 Year would result in - of your transactions generating a profit, with an average return of -139.50% per trade.
2 Years
No data currently available
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
ONCO Analyst Recommendation Trends
Rating
Jun 25
Jul 25
Aug 25
Oct 25
Nov 25
Strong Buy
0
0
0
0
0
Buy
0
0
0
0
0
Hold
1
11
11
13
6
Sell
2
1
1
0
0
Strong Sell
0
0
0
0
0
total
3
12
12
13
6
In the current month, ONCO has received 0Buy Ratings, 6Hold Ratings, and 0Sell Ratings. ONCO average Analyst price target in the past 3 months is ―.
Each month's total comprises the sum of three months' worth of ratings.
ONCO Stock Forecast FAQ
What is SE:ONCO’s average 12-month price target, according to analysts?
Currently, no data Available
What is SE:ONCO’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for SE:ONCO, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Oncopeptides AB a Buy, Sell or Hold?
Currently, no data Available
What is Oncopeptides AB’s share price target?
Currently, no data Available
What do analysts say about Oncopeptides AB?
Not enough analysts have published a price target to provide an average price target.
How can I buy shares of Oncopeptides AB?
To buy shares of SE:ONCO, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.